| pubmed-article:15780613 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15780613 | lifeskim:mentions | umls-concept:C0284930 | lld:lifeskim |
| pubmed-article:15780613 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:15780613 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:15780613 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:15780613 | lifeskim:mentions | umls-concept:C0439596 | lld:lifeskim |
| pubmed-article:15780613 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:15780613 | pubmed:dateCreated | 2005-3-22 | lld:pubmed |
| pubmed-article:15780613 | pubmed:abstractText | Starting from a PDE IV inhibitor hit derived from high throughput screening of the compound collection, a key pyrrolidine cyanamide pharmacophore was identified. Modifications of the pyrrolidine ring produced enhancements in cathepsin K inhibition. An X-ray co-crystal structure of a cyanamide with cathepsin K confirmed the mode of inhibition. | lld:pubmed |
| pubmed-article:15780613 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15780613 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15780613 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15780613 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15780613 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15780613 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15780613 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15780613 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15780613 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15780613 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15780613 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:15780613 | pubmed:issn | 0960-894X | lld:pubmed |
| pubmed-article:15780613 | pubmed:author | pubmed-author:DeatonDavid... | lld:pubmed |
| pubmed-article:15780613 | pubmed:author | pubmed-author:MillerAaron... | lld:pubmed |
| pubmed-article:15780613 | pubmed:author | pubmed-author:WrightLois... | lld:pubmed |
| pubmed-article:15780613 | pubmed:author | pubmed-author:HassellAnne... | lld:pubmed |
| pubmed-article:15780613 | pubmed:author | pubmed-author:ShewchukLisa... | lld:pubmed |
| pubmed-article:15780613 | pubmed:author | pubmed-author:McFadyenRober... | lld:pubmed |
| pubmed-article:15780613 | pubmed:author | pubmed-author:MillerLarry... | lld:pubmed |
| pubmed-article:15780613 | pubmed:author | pubmed-author:WillardDerril... | lld:pubmed |
| pubmed-article:15780613 | pubmed:author | pubmed-author:TavaresFranci... | lld:pubmed |
| pubmed-article:15780613 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15780613 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:15780613 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:15780613 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15780613 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15780613 | pubmed:pagination | 1815-9 | lld:pubmed |
| pubmed-article:15780613 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:15780613 | pubmed:meshHeading | pubmed-meshheading:15780613... | lld:pubmed |
| pubmed-article:15780613 | pubmed:meshHeading | pubmed-meshheading:15780613... | lld:pubmed |
| pubmed-article:15780613 | pubmed:meshHeading | pubmed-meshheading:15780613... | lld:pubmed |
| pubmed-article:15780613 | pubmed:meshHeading | pubmed-meshheading:15780613... | lld:pubmed |
| pubmed-article:15780613 | pubmed:meshHeading | pubmed-meshheading:15780613... | lld:pubmed |
| pubmed-article:15780613 | pubmed:meshHeading | pubmed-meshheading:15780613... | lld:pubmed |
| pubmed-article:15780613 | pubmed:meshHeading | pubmed-meshheading:15780613... | lld:pubmed |
| pubmed-article:15780613 | pubmed:meshHeading | pubmed-meshheading:15780613... | lld:pubmed |
| pubmed-article:15780613 | pubmed:meshHeading | pubmed-meshheading:15780613... | lld:pubmed |
| pubmed-article:15780613 | pubmed:meshHeading | pubmed-meshheading:15780613... | lld:pubmed |
| pubmed-article:15780613 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15780613 | pubmed:articleTitle | Novel and potent cyclic cyanamide-based cathepsin K inhibitors. | lld:pubmed |
| pubmed-article:15780613 | pubmed:affiliation | Department of Medicinal Chemistry, GlaxoSmithKline, Research Triangle Park, NC 27709, USA. david.n.deaton@gsk.com | lld:pubmed |
| pubmed-article:15780613 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:15780613 | lld:chembl |
